본문 바로가기
  • Home

Metformin-loaded Citric Acid Cross-linked Agarose Films in the Prevention of Postoperative Abdominal Adhesion

  • Anatomy & Biological Anthropology
  • Abbr : Anat Biol Anthropol
  • 2019, 32(4), pp.129~139
  • DOI : 10.11637/aba.2019.32.4.129
  • Publisher : 대한체질인류학회
  • Research Area : Medicine and Pharmacy > Anatomy
  • Received : October 21, 2019
  • Accepted : October 24, 2019
  • Published : December 31, 2019

Ji Hyun Moon 1 Jong Ho Park 2 JEONG JI HEUN ORD ID 3 Naksong Sung 4 Jeong Young Gil 3 Ki Chang Song 3 Jong Pil Ahn 5 Nam Seob Lee 3 Seung yun, Han 3

1Department of Anatomy, College of Medicine, Konyang University
2Department of Biomedical Material, College of Medical Engineering, Konyang University
3건양대학교
4Department of General Surgery, Konyang University Hospital
5Korea Institute of Ceramic Engineering and Technology

Accredited

ABSTRACT

Postoperative abdominal adhesion (PAA) causes significant long-term postoperative morbidity. Although numerous physical anti-adhesion barriers (AAB) are used as therapeutical interventions, none of them has achieved sustained success. As a potential strategy to overcome the limitations, drug-eluting AAB have attracted scientific attention. Here, we produced agar films (AF) chemically cross-linked with different concentrations of citric acid (CA) and we measured the physicochemical properties such as crosslinking strength, swelling ratio, hydrophilicity, and biodegradability of the yielded CA-AFs. Next, Metformin (MET), an antidiabetic drug with anti-proliferative and anti-inflammatory properties, was loaded in the CA-AFs yielding the MET-loaded CA-AF (MET@CA-AF) and the time-dependent MET release was monitored. Based on their physicochemical properties, MET@CA-AF containing 20% CA appeared a promising AAB candidate and was further used in an in vivo study. Mouse models of PAA were established with cecum abrasion and the MET@CAAF and CA-AF were applied between the injured interfaces. At postoperative day 14, the therapeutic efficacies were analyzed by using clinical adhesion scoring and quantification of collagen-I and fibroblasts in adhesion interfaces. The results showed that applications of MET@CA-AF or CA-AF for 14 days significantly attenuated the clinical adhesion score and thickness of adhesion interface. Furthermore, when compared with the group with operation, the groups with MET@CA-AF or CA-AF exhibited the significant attenuation in PAA-associated myofibroblast activation in adhesion interface. Importantly, these attenuations were significantly more intensified in the group with MET@CA-AF than in the group with CA-AF. Based on our data, we anticipate that MET@CAAF, a novel synthesized drug-eluting AAB, can protect against PAA by exerting the dual role of physical barrier and MET-based pharmaceutic.

Citation status

* References for papers published after 2023 are currently being built.

This paper was written with support from the National Research Foundation of Korea.